These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 1712375

  • 21. A selective bi-site immunoenzymatic procedure for human Lp[a] lipoprotein quantification using monoclonal antibodies against apo[a] and apoB.
    Vu Dac N, Mezdour H, Parra HJ, Luc G, Luyeye I, Fruchart JC.
    J Lipid Res; 1989 Sep; 30(9):1437-43. PubMed ID: 2532239
    [Abstract] [Full Text] [Related]

  • 22. Isolation and characterization of three monoclonal antibodies to human serum low density lipoprotein apoprotein B.
    Aggerbeck LP, Caron F, Lachacinski N, Bouma ME.
    Biochimie; 1986 Apr; 68(4):531-41. PubMed ID: 2427125
    [Abstract] [Full Text] [Related]

  • 23. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments.
    Rouy D, Koschinsky ML, Fleury V, Chapman J, Anglés-Cano E.
    Biochemistry; 1992 Jul 14; 31(27):6333-9. PubMed ID: 1627572
    [Abstract] [Full Text] [Related]

  • 24. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a).
    Edelstein C, Pfaffinger D, Hinman J, Miller E, Lipkind G, Tsimikas S, Bergmark C, Getz GS, Witztum JL, Scanu AM.
    J Biol Chem; 2003 Dec 26; 278(52):52841-7. PubMed ID: 14557258
    [Abstract] [Full Text] [Related]

  • 25. Relative topography of biologically active domains of human vitronectin. Evidence from monoclonal antibody epitope and denaturation studies.
    Morris CA, Underwood PA, Bean PA, Sheehan M, Charlesworth JA.
    J Biol Chem; 1994 Sep 23; 269(38):23845-52. PubMed ID: 7522235
    [Abstract] [Full Text] [Related]

  • 26. Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay.
    Taddei-Peters WC, Butman BT, Jones GR, Venetta TM, Macomber PF, Ransom JH.
    Clin Chem; 1993 Jul 23; 39(7):1382-9. PubMed ID: 7687203
    [Abstract] [Full Text] [Related]

  • 27. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody.
    Kang C, Dominguez M, Loyau S, Miyata T, Durlach V, Anglés-Cano E.
    Arterioscler Thromb Vasc Biol; 2002 Jul 01; 22(7):1232-8. PubMed ID: 12117743
    [Abstract] [Full Text] [Related]

  • 28. The linkage with apolipoprotein (a) in lipoprotein (a) modifies the immunochemical and functional properties of apolipoprotein B.
    Zawadzki Z, Tercé F, Seman LJ, Theolis RT, Breckenridge WC, Milne RW, Marcel YL.
    Biochemistry; 1988 Nov 01; 27(22):8474-81. PubMed ID: 2468359
    [Abstract] [Full Text] [Related]

  • 29. Lipoprotein(a), fibrin binding, and plasminogen activation.
    Loscalzo J, Weinfeld M, Fless GM, Scanu AM.
    Arteriosclerosis; 1990 Nov 01; 10(2):240-5. PubMed ID: 2138452
    [Abstract] [Full Text] [Related]

  • 30. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.
    Rouy D, Grailhe P, Nigon F, Chapman J, Anglés-Cano E.
    Arterioscler Thromb; 1991 Nov 01; 11(3):629-38. PubMed ID: 1827591
    [Abstract] [Full Text] [Related]

  • 31. Anti-human IgE monoclonal antibodies recognizing epitopes related to the binding sites of high and low affinity IgE receptors.
    Takemoto H, Nishimura S, Kosada Y, Hata S, Takagi S, Hosoi S, Ezumi K, Ide M, Harada S.
    Microbiol Immunol; 1994 Nov 01; 38(1):63-71. PubMed ID: 7519718
    [Abstract] [Full Text] [Related]

  • 32. Neutrophils stimulated by apolipoprotein(a) generate fragments that are stronger inhibitors of plasmin formation than apo(a).
    Lamanuzzi LB, Mtairag el M, Pepe G, Anglés-Cano E.
    Thromb Haemost; 2004 Nov 01; 92(5):1066-75. PubMed ID: 15543335
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Inhibition of fibrinolysis by lipoprotein(a).
    Anglés-Cano E, de la Peña Díaz A, Loyau S.
    Ann N Y Acad Sci; 2001 Nov 01; 936():261-75. PubMed ID: 11460483
    [Abstract] [Full Text] [Related]

  • 35. Characterization of monoclonal antibodies against human tissue plasminogen activator (tPA): quantitation of free tPA in human cell cultures by an ELISA.
    Kurokawa T, Toyoda Y, Iwasa S.
    J Biochem; 1991 Feb 01; 109(2):217-22. PubMed ID: 1713912
    [Abstract] [Full Text] [Related]

  • 36. Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator.
    Anglés-Cano E, Hervio L, Rouy D, Fournier C, Chapman JM, Laplaud M, Koschinsky ML.
    Chem Phys Lipids; 1994 Jan 01; 67-68():369-80. PubMed ID: 8187237
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Enzyme-linked immunoassay for Lp[a].
    Fless GM, Snyder ML, Scanu AM.
    J Lipid Res; 1989 May 01; 30(5):651-62. PubMed ID: 2527286
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.